tiprankstipranks
Trending News
More News >
Heidelberg Pharma AG (DE:HPHA)
XETRA:HPHA
Advertisement

Heidelberg Pharma AG (HPHA) AI Stock Analysis

Compare
5 Followers

Top Page

DE:HPHA

Heidelberg Pharma AG

(XETRA:HPHA)

Rating:42Neutral
Price Target:
€4.00
▼(-8.68% Downside)
Heidelberg Pharma AG's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and significant losses. Technical analysis provides mixed signals, while valuation metrics are unattractive due to negative profitability. The absence of earnings call data and corporate events limits additional insights.

Heidelberg Pharma AG (HPHA) vs. iShares MSCI Germany ETF (EWG)

Heidelberg Pharma AG Business Overview & Revenue Model

Company DescriptionHeidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
How the Company Makes MoneyHeidelberg Pharma AG generates revenue through multiple channels, primarily focusing on the development and commercialization of its proprietary drug candidates. The company's revenue model includes funding from partnerships with other pharmaceutical firms, where they collaborate on the development of ATAC-based therapies. These partnerships often involve upfront payments, milestone payments upon achieving specific development goals, and royalties on future sales of products that result from these collaborations. Additionally, HPHA may receive funding from government grants and venture capital investments aimed at advancing its research initiatives. The company's potential for earnings is significantly influenced by the successful advancement of its drug candidates through clinical trials and subsequent commercialization.

Heidelberg Pharma AG Financial Statement Overview

Summary
Heidelberg Pharma AG is facing financial challenges with declining revenues, significant operating losses, and negative cash flows. While the balance sheet shows some stability, the high liabilities and declining equity may pose future risks. The company needs to improve operational efficiency and manage its financial structure to enhance profitability and liquidity.
Income Statement
45
Neutral
Heidelberg Pharma AG shows decreasing revenue and negative profit margins, with a declining revenue growth rate from recent years. The company struggles with high EBIT and EBITDA losses, indicating operational inefficiencies.
Balance Sheet
55
Neutral
The balance sheet displays a moderate debt-to-equity ratio and a reasonable equity ratio. However, the declining stockholders' equity and high total liabilities indicate potential financial instability.
Cash Flow
50
Neutral
The company exhibits negative operating and free cash flows, which could affect its liquidity. Free cash flow has been consistently negative, but financing activities provide some cash influx. The ratios indicate challenges in converting revenue into cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.18M6.85M9.86M18.51M1.75M8.49M
Gross Profit3.22M4.20M6.61M13.83M-2.96M2.89M
EBITDA-22.43M-18.37M-18.71M-16.19M-24.83M-17.55M
Net Income-23.31M-19.38M-20.35M-19.70M-26.63M-18.37M
Balance Sheet
Total Assets62.45M60.72M70.35M100.58M21.73M19.61M
Cash, Cash Equivalents and Short-Term Investments33.25M29.42M43.44M81.33M6.14M4.98M
Total Debt122.23K21.97M5.83M15.98M10.63M202.68K
Total Liabilities43.94M29.85M21.01M33.94M15.03M6.73M
Stockholders Equity18.52M30.87M49.34M66.64M6.70M12.88M
Cash Flow
Free Cash Flow-27.21M-30.04M-34.63M-9.48M-28.00M-19.33M
Operating Cash Flow-26.78M-29.59M-33.67M-8.86M-26.61M-17.89M
Investing Cash Flow-445.00K-449.13K5.85M-597.57K-1.40M-1.29M
Financing Cash Flow17.96M16.08M-10.05M84.00M29.17M14.29M

Heidelberg Pharma AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.38
Price Trends
50DMA
4.35
Positive
100DMA
3.81
Positive
200DMA
3.14
Positive
Market Momentum
MACD
<0.01
Negative
RSI
52.09
Neutral
STOCH
28.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HPHA, the sentiment is Positive. The current price of 4.38 is above the 20-day moving average (MA) of 4.31, above the 50-day MA of 4.35, and above the 200-day MA of 3.14, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.09 is Neutral, neither overbought nor oversold. The STOCH value of 28.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:HPHA.

Heidelberg Pharma AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
€1.88B21.9212.16%2.05%7.83%13.92%
42
Neutral
€202.00M-78.11%-56.07%-78.48%
€5.03M-288.87%
€1.38B61.76-4.72%
€44.35M-111.86%
$423.35M20.943.56%
57
Neutral
€440.81M5.89-34.48%-14.84%-338.52%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:HPHA
Heidelberg Pharma AG
4.38
1.91
77.33%
GB:0R6U
4SC AG
7.82
0.00
0.00%
GB:0N6Z
Biotest
41.20
-0.80
-1.90%
GB:0RFI
B.R.A.I.N. Biotechnology Research and Information Network
2.09
0.33
18.75%
MEDOF
Medios AG
16.87
-1.71
-9.20%
DE:FYB
Formycon AG
24.50
-28.60
-53.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 12, 2025